JW (Cayman) Therapeutics Co. Ltd (JWCTF)
Stock analysis · OTC · Healthcare · Biotechnology
JW (Cayman) Therapeutics Co. Ltd (JWCTF) is a publicly traded company in the Healthcare sector. Latest price: $0.20. Market cap $84.28M. Trailing PE -2.37. Sign in to Stocks360 for full DCF valuation, fundamentals, technicals, and AI-driven analysis.
Get full analysis → Short-Term Analysis →You have viewed 4 SEO analysis pages
Unlock saved watchlists, personalized setups, and referral credits with a free Stocks360 account.
Continue with free signup1-Year Price
Earnings
Proprietary Signals
About JW (Cayman) Therapeutics Co. Ltd
JW (Cayman) Therapeutics Co. Ltd is a biopharmaceutical entity currently in the clinical development phase, dedicated to the discovery, manufacturing, and commercialization of advanced cell-based immunotherapeutic solutions. Its core mission is to combat both hematological cancers (blood cancers) and various solid tumors. The company's innovative treatments encompass cell-derived immunotherapies, particularly Chimeric Antigen Receptor T-cell (CAR-T) therapies, which leverage a patient's own immune cells to target and eliminate cancerous cells. Leading its clinical efforts is Carteyva (relmacabtagene autoleucel), an anti-CD19 CAR-T therapeutic agent aimed at various forms of blood cancer. Beyond its flagship product, JW (Cayman) Therapeutics maintains a promising product pipeline. This includes JWCAR129, an autologous CAR-T therapy for treating multiple myeloma; JWATM204, a T-cell receptor (TCR) T-cell therapy candidate for hepatocellular carcinoma (HCC); and JWATM203, another autologous T-cell therapy that mimics T-cell receptors, specifically designed to target alpha-fetoprotein in HCC. Established in 2016, JW (Cayman) Therapeutics Co. Ltd is headquartered in Shanghai, People's R…
Valuation
| P/E (TTM) | -2.37× |
|---|---|
| P/S (TTM) | 2.76× |
| P/B | 1.74× |
| P/FCF (TTM) | -7.05× |
| EV / EBITDA | -3.26× |
| EV / Sales | 2.28× |
| Earnings Yield | -42.30% |
| Free Cash Flow Yield | -14.19% |
Fundamentals
| Enterprise Value | $651.99M |
|---|---|
| Revenue (TTM) | $285.83M |
| Net Income (TTM) | -$333.81M |
| Free Cash Flow (TTM) | -$103.66M |
| Net Debt | -$137.17M |
| Working Capital | $136.20M |
| Gross Margin | 39.80% |
| Operating Margin | -95.03% |
| Net Margin | -116.75% |
| Return on Equity | -66.16% |
| Return on Invested Capital | -38.41% |
Peers
Recent News
- No recent news available.
Related
Browse more tickers: sitemap